<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652479</url>
  </required_header>
  <id_info>
    <org_study_id>52880</org_study_id>
    <nct_id>NCT04652479</nct_id>
  </id_info>
  <brief_title>Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia</brief_title>
  <official_title>A Phase 2, Open-Label, Cross-over Study to Assess the Safety and Efficacy of Avexitide in Acquired Hyperinsulinemic Hypoglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Tracey McLaughlin, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eiger BioPharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to evaluate the safety and efficacy of two different dosing&#xD;
      regimens of an investigational drug called Avexitide in treating low blood sugar in patients&#xD;
      with Acquired Hyperinsulinemic Hypoglycemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of diurnal Level 2 hypoglycemia events (ADA, &lt;54 mg/dL) as measured by CGM in patients with severe HH</measure>
    <time_frame>14 Days</time_frame>
    <description>Change from Baseline in Rate of Level 2 Hypoglycemia measured by CGM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Level 2 hypoglycemia (ADA, &lt;54 mg/dL) as measured by SMBG</measure>
    <time_frame>14 Days</time_frame>
    <description>Change from Baseline in Rate of Level 2 Hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Level 3 Hypoglycemia</measure>
    <time_frame>14 Days</time_frame>
    <description>Change from Baseline in Rate of Level 3 Hypoglycemia (Severe Hypoglycemia)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent diurnal time &lt;54 mg/dL as measured by CGM</measure>
    <time_frame>14 Days</time_frame>
    <description>Change from Baseline in Percent diurnal time with Clinically Important Hypoglycemia (&lt; 54mg/dL by Continuous Glucose Monitor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glycemia during standardized mixed meal consumption</measure>
    <time_frame>3 Hours Following Standardized Liquid Meal</time_frame>
    <description>Change from Baseline in glycemia During Standardized Mixed Meal Consumption</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acquired Hyperinsulinemic Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days (in the opposite sequence from Treatment Group 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avexitide</intervention_name>
    <description>Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor</description>
    <arm_group_label>Treatment Group 1</arm_group_label>
    <arm_group_label>Treatment Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of bariatric or upper-gastrointestinal surgery (RYGB, VSG, gastrectomy,&#xD;
             esophagectomy, or Nissen fundoplication) at least 12 months prior to the start of&#xD;
             Screening&#xD;
&#xD;
          -  History of recurrent hypoglycemia occurring after bariatric or upper-GI surgery, as&#xD;
             documented in the medical record.&#xD;
&#xD;
          -  Body mass index (BMI) of up to 40 kg/m2&#xD;
&#xD;
          -  If female, must not be breastfeeding and must have a negative urine pregnancy test&#xD;
             result&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery within 6 months before randomization.&#xD;
&#xD;
          -  History of or current hyperinsulinism other than Acquired Hyperinsulinism (e.g.,&#xD;
             insulin autoimmune hypoglycemia).&#xD;
&#xD;
          -  Use of agents that may interfere with glucose metabolism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marilyn Tan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>(650) 721-1300</phone>
    <email>tshamloo@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marilyn Tan</last_name>
    <phone>(650) 721-1300</phone>
    <email>mjtan@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical and Translational Research Unit</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Termeh Shamloo</last_name>
      <email>tshamloo@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Marilyn Tan</investigator_full_name>
    <investigator_title>Clinical Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Post Bariatric Hypoglycemia</keyword>
  <keyword>avexitide</keyword>
  <keyword>Post-Bariatric Hypoglycemia</keyword>
  <keyword>Post-gastrectomy hypoglycemia</keyword>
  <keyword>Post gastrectomy hypoglycemia</keyword>
  <keyword>Post-esophagectomy hypoglycemia</keyword>
  <keyword>Post esophagectomy hypoglycemia</keyword>
  <keyword>Post-Nissen Fundoplication hypoglycemia</keyword>
  <keyword>Post Nissen Fundoplication hypoglycemia</keyword>
  <keyword>Exendin (9-39)</keyword>
  <keyword>Exendin 9-39</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

